| Term 
 
        | general mechanism of action |  | Definition 
 
        | all these drugs alter the transport of ions = altering the conentration of chemicals (neurotransmitters) at synapses   one exception: antiseizure drugs act by altering membrane potentials along axon   |  | 
        |  | 
        
        | Term 
 
        | mechanism of action of antiseizure drugs |  | Definition 
 
        | alter membrane potentials along axons |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | - restricts entery of drugs into the CNS - due to tight junctions between endothelial cells in the capillaries in the brain - no such thing in peripheral nervous system |  | 
        |  | 
        
        | Term 
 
        | so how do you bypass the blood-brain barrier? |  | Definition 
 
        | 1) lipophilic drugs 2) transport into the CNS via transporters that are normally for nutrients 3) inflammation of the meninges or the brain |  | 
        |  | 
        
        | Term 
 
        | what does P-glycoprotein do? |  | Definition 
 
        | it is a nonspecific transporter that actively transports drugs out of the brain |  | 
        |  | 
        
        | Term 
 
        | resting membrane potential |  | Definition 
 
        | -70 mv   kept by the Na-K ATPase (Na pumped out, K in)   Cl also going out |  | 
        |  | 
        
        | Term 
 
        | voltage gated ion channels |  | Definition 
 
        | PROPIGATION OF THE ACTION POTENTIAL   Sodium rushes in through voltage-gated Na channels (these channels are present on nerve and muscle cells) - open in response to depolarization to further depolarize (or repolarize) the membrane |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | potassium floods out via K+ leak channels |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | channel opens in response to bidning of a neurotransmitter -- responsible for synaptic transmission |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks neurotransmitter storage |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | blocks reuptake (MOA in synapse) |  | 
        |  | 
        
        | Term 
 
        | what do cholinesterase inhibitors do? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | they affect the receptors on the post-synaptic neuron |  | 
        |  | 
        
        | Term 
 
        | what does amphetamine do? |  | Definition 
 
        | Increases neurotransmitter release |  | 
        |  | 
        
        | Term 
 
        | heirarchical neural systems |  | Definition 
 
        | anatomically well defined systems, in particular the sensory and motor systems   generally utilize amino acids as neurotransmitters |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anatomically less well-defined   tend to be implicated in global functions   utilize monoamines and peptides as neurotransmitters |  | 
        |  | 
        
        | Term 
 
        | monoamine neurotransmitters in the CNS |  | Definition 
 
        | 1) Norepinephrine 2) Dopamine 3) Serotonin (5-HT neurons) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cell bodies found in: 1) Pons (locus ceruleus) 2) Midbrain   Project diffusely to virtually all regions of the crebral cortex and limbic system   regulates arousal and mood |  | 
        |  | 
        
        | Term 
 
        | what determines specificy of NE-releasing neurons? |  | Definition 
 
        | cellular targets are determined by the location and  pattern of postsynaptic receptors rather than the location of the release sites |  | 
        |  | 
        
        | Term 
 
        | α1,β1 receptors (NE system) |  | Definition 
 
        | these are excitatory - decrease the rectifying K conductance |  | 
        |  | 
        
        | Term 
 
        | α2,β2 receptors (NE system) 
 |  | Definition 
 
        | inhibitory - increase the rectifying K conductance |  | 
        |  | 
        
        | Term 
 
        | clinical considerations for NE |  | Definition 
 
        | noradrenergic neurons in the limbic system are thought to be a major target for antidepressant medications (which increase the amount of NE in the synapse, so there is a downregulation of receptors on postsynaptic cell- especially β2) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1) anatomically more limited than noradrenergic neurons 2) extrapyramidal motor control (site of action of antiparkinson drugs) 3) limibic system (site of action of antipsychotic drugs) 4) hypothalamic-pituitary axis |  | 
        |  | 
        
        | Term 
 
        | how many dopamine receptor subtypes are there? |  | Definition 
 
        | five receptor subtypes 
 fall into D1 or D2 family 
 D1 - Agonist = none in use - Antagonist= phenothiazines 
 D2 - Agonist = bromocriptine -Antagonist=phenothiazines
 |  | 
        |  | 
        
        | Term 
 
        | the three important ascending dopaminergic pathways |  | Definition 
 
        | 1) Nigrostriatal - extrapyramidal motor control - important for movement disorders (parkinson's, Frozen Man Syndrome)   2) Tuberoinfundibular (neuroendocrine regulation)   3) Mesolimbic (emotions, reward system) |  | 
        |  | 
        
        | Term 
 
        | what does dopamine generally do, inhibit or excite? |  | Definition 
 
        | generally inhibits neuronal activity |  | 
        |  | 
        
        | Term 
 
        | dopamine clinical considerations |  | Definition 
 
        | 1) Nigrostriatal Pathway = Parkinson's (selective cell death), MPTP Frozen Man syndrome (toxin transported into neurons)   2) Substantia nigra to limbic system and widespread cortex = addiction and behavioral disorders 
 3) Arcuate nucleus of hypothalamus to anterior pituitary (via portal veins): inhibits prolactin secretion
 |  | 
        |  | 
        
        | Term 
 
        | serotonin/5-HT - location of neurons |  | Definition 
 
        | most cell bodies = in midline region of the pons;   project diffusely to most of the CNS (ascend to the cerebral cortex and limbic system from the midline tegmentum (raphe nucleus) |  | 
        |  | 
        
        | Term 
 
        | what functions do serotonin neurons control? |  | Definition 
 
        | -regulating emotions - sleep-wake cycles -temperature control |  | 
        |  | 
        
        | Term 
 
        | clinical consideration for serotonin |  | Definition 
 
        | Antipsychotics and antidepressants 
 1) mood disorders (SSRIs improve depression) 
 2) migrane pain 
 3) chemotherapy-induced emesis (ondasetron 5-HT3 antagonist) 
 4) LSD activates 5-HT1 and 2 receptors
 |  | 
        |  | 
        
        | Term 
 
        | basic information about ACh |  | Definition 
 
        | both long and short cholinergic pathways are present at all levels of the CNS, particularly cerebral cortex and limbic system   most CNS effects are mediated by a large family of muscarinic receptors (slow excitation)   implicated in cognitive function (esp. MEMORY)   action is terminated by cholinesterase |  | 
        |  | 
        
        | Term 
 
        | what type of muscarinic receptors predominate in the CNS? |  | Definition 
 
        | Answer: M1 type - they slowly open the rectifying potassium channel causing slow excitation   (Nicotinic and M2 receptors are present, but in much lower density) |  | 
        |  | 
        
        | Term 
 
        | Clinical considerations for ACh |  | Definition 
 
        | 1) Motor neurons in spinal cord to the NMJ - acetylcholinesterases (nerve gases), insecticides; myasthenia gravis; botulism   2) basal forebrain to cortex - Alzheimer's disease (selective cell death/atrophy = cognitive defects --> tacrine, donepizil, galantamine, rivastigmine are CE inhibitors used for Alzheimer's tx); 
 autosomal dominant frontal lobe epilepsy (mutations in CNS ACh receptor)   3) Atrophy of neurons in extrappyramidal system is thought to contribute to the tremor in Parkinson's |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | amino acid NT   cell bodies found primarily in the spinal cord   INHIBITS NEURAL ACTIVITY   Strychnine (poison) antagonizes glycine inhibition by blocking the glycine receptor --> convulsions |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mediates inhibitory actions of local interneurons   found in: - cerebellum -cerebral cortex -limbic system   two receptor subtypes: GABA-A, GABA-B |  | 
        |  | 
        
        | Term 
 
        | Clinical consideration for GABA |  | Definition 
 
        | 1) Major inhibitory NT in brain: sedative - hypnotic drugs act by facilitating the action of GABA   barbituates in high does can directly activate the GABA receptor -- profound respiratory depression and CV collapse   2) Epilepsy - gabapentin and valproic acid increase GABA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | widely distributed in the CNS,   generally excitatory 
 two major classes of receptors: NMDA and non-NMDA 
 NMDA: blocked by ketamine, PCP; activated by a new class of antipsychotics
 |  | 
        |  | 
        
        | Term 
 
        | clinical considerations for glutamate |  | Definition 
 
        | 1) tranquilizing/anesthetic agents - ketamine and phencyclidine; act by blocking the NMDA receptor --> disordered thinking similar to schizophrenia   2) antiphyschotic drugs in develoment are NMDA agonists |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | these proteins are cleavage products of a larger peptide (pro-opiomelanocortin)   are part of endorphin/enkephalin families --> variety of receptors; generally inhibitory   endogenous ligands for the opioid receptors |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 167 amino acid long - secreted only by adipose tissue (not strictly a NT)   its receptors are found in the CNS   obese individuals have INCREASED levels   binds to ventromedial hypothalamus to induce satiety and increase lipogenesis (obesity = leptin insensitivity)     |  | 
        |  | 
        
        | Term 
 
        | other peptide neurotransmitters |  | Definition 
 
        | Present in gut and endocrine tissues and in CNS: 
vasoactive intestinal peptide (VIP)cholecystokinin (CCK)thryotropin releasing hormone (TRH)somatostatin     Substance P = transmission of pain |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Receptor = CB1 = is widely distributed in the CNS -- are primarily presynaptic 
 endogenous ligands are thought to be brain lipids (which is different from other NTs because these are NOT STORED. Instead, they are synthesized in response to stimuli and act in a retrograde fashion) 
 secreted from the postsynaptic neuron and bind on CB1 on presynaptic neuron --> inhibit neurotransmitter release 
 Activation of these receptors affects: memory, cognition, and pain perception
 |  | 
        |  | 
        
        | Term 
 
        | fnx of inhibitory ligand-gated receptor? |  | Definition 
 
        | ligand binding causes the receptor to hyperpolarize the membrane by increasing the chloride ion flux |  | 
        |  |